BioLineRx Ltd. (NASDAQ: BLRX) announced today the filing of regulatory submissions required to commence a Phase 2 trial for BL-8040 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE